Wednesday, July 01, 2020
Sinclair Research, a leading provider of nonclinical contract research services, today announced completion of successful validation of GLP ototoxicity testing services in partnership with Turner Scientific, an industry leader specializing in nonclinical hearing research.
“Sinclair’s validated GLP ototoxicity testing services provide drug developers with more research options,” Andy Brown, Sinclair Research’s Vice President of Commercial Operations said. “As a result of our partnership with Turner Scientific, Sinclair Research is one of the only CROs that can offer GLP auditory safety research services, and we are excited to offer GLP ototoxicity testing along with IND-enabling nonclinical toxicology services at a single-site CRO.”
The partnership with Turner Scientific allows Sinclair Research to help drug developers effectively evaluate the risks of potential auditory damage prior to first-in-human trials, and will help safeguard developers from potential risk while also helping them get their products to market faster and safer than before.
Ototoxicity studies evaluate the safety and potential adverse effects a compound or device has on the inner ear and auditory nerves, which can lead to symptoms including dizziness, vertigo, tinnitus and hearing loss.
The partnership also allows both companies to provide experimental toxicology and efficacy services in auditory research for novel biopharmaceuticals and cell and gene therapies.
“Working together with Sinclair Research combines our more than 20 years of conducting auditory research with Sinclair’s experience in conducting quality nonclinical research,” Turner Scientific’s Chief Scientific Officer Dr. Jeremy Turner said. “These successful validation studies provided accurate, high-confidence data and conclusively demonstrated the high-quality auditory research support that Turner Scientific and Sinclair Research are able to provide drug developers.”